Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain Shams University Hospitals

Clinical trial NCT07088081 · ENROLLING_BY_INVITATION

Trial details

NCT number: NCT07088081
Sponsor: Ain Shams University
Status: ENROLLING_BY_INVITATION
Study type: OBSERVATIONAL

HCC - Hepatocellular Carcinoma Immunotherapy Immune Checkpoint Therapy Immune Checkpoint Inhibitor-Induced Dermatitis Atezolizumab and Bevacizumab in Hepatocellular Carcinoma Durvalumab

Start date: 2025-06-01
Primary completion: 2026-06-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.